Merck (MRK) PT Raised to $81 at Credit Suisse on Keytruda and Multiple Options
Tweet Send to a Friend
Credit Suisse analyst Vamil Divan raised the price target on Merck (NYSE: MRK) to $81.00 (from $71.00) while maintaining an ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
